Skip to main content
. 2014 Aug 1;17(1):81–94. doi: 10.1093/neuonc/nou144

Fig. 4.

Fig. 4.

In vitro migration of GBM cells in response to recombinant CXCL12 and subventricular zone-conditioned medium (SVZ-CM). (A and B) Recombinant CXCL12 triggered migration and chemotaxis of human U87MG cells. (C and D) SVZ-CM triggered migration and chemotaxis of human U87MG cells. (E) The migration of U87MG cells and human GBM cells in primary culture (GBM2) in response to SVZ-CM was significantly reduced by using AMD3100, a specific CXCR4 antagonist. (F) AMD3100 disrupted chemotaxis of U87MG cells in response to SVZ-CM. (G and H) AMD3100 did not impact parameters such as the mean accumulated distance (µm) and velocity (µm/min) of U87MG cells. (I) U87MG-SVZ cells showed greater migration abilities in response to recombinant CXCL12 and SVZ-CM compared with U87MG cells or U87MG-TM cells. Moreover, AMD3100 clearly inhibited the migration of U87MG-SVZ cells in response to SVZ-CM. Graphs are mean values ± SEM and are representative of 3 independent experiments. *P < .05; **P < .01; ***P < .001; ns, not significant.